At 5-year follow-up , significant prolonged overall survival ( OS ) and relapse-free survival ( RFS ) times were seen with the addition of TAM in patients with ER-positive and Stage IIIA T3N0 cancer ( 1987 UICC-American Joint Committee on Cancer [ AJCC ] criteria ) ; however , no significant survival benefit from TAM was seen in patients with ER-positive and Stage IIA T2N1 cancer .
